| |
|
|
|
|
|
 |
| |
|
¸¶ÀÌÅä´ÑÁ¤ 25mg(º£Å¸³×ÄÝ¿°È¹°) Mytonin Tab. 25mg
|
Àü¹®ÀǾàǰ | ±Þ¿©
|
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
 |
Á¦Ç°º° ÀӺαݱ⠰í½Ã |
|
|
|
1µî±Þ: ¿øÄ¢Àû »ç¿ë±Ý±â / 2µî±Þ: ¸íÈ®ÇÑ ÀÓ»óÀû ±Ù°Å ¶Ç´Â »çÀ¯°¡ ÀÖ´Â °æ¿ì ºÎµæÀÌÇÏ°Ô »ç¿ë / Mµî±Þ: ÀÓ»óÀû»óȲ¿¡ µû¶ó 1µî±Þ ¶Ç´Â 2µî±ÞÀ¸·Î ºÐ·ùµÇ´Â ¼ººÐ
| ¼ººÐ¸í |
¼ººÐÄÚµå |
±Ý±âµî±Þ |
°í½Ã¹øÈ£ |
°í½ÃÀÏÀÚ |
ºñ°í |
| bethanechol |
116902ATB |
2 |
20160155 |
20161230 |
ÀӺο¡ ´ëÇÑ ¾ÈÀü¼º ¹ÌÈ®¸³. |
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
652603680
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\205 ¿ø/1Á¤(2017.02.01)(ÇöÀç¾à°¡)
\205 ¿ø/1Á¤(2015.10.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
Ȳ»öÀÇ ¿øÇü Á¤Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
100Á¤(10Á¤/PTPX10) |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 25¹Ð¸®±×·¥ |
300 Á¤ |
º´ |
8806526036804 |
8806526036835 |
|
| 25¹Ð¸®±×·¥ |
100 Á¤ |
º´ |
8806526036804 |
8806526036828 |
|
| 25¹Ð¸®±×·¥ |
100 Á¤ |
PTP |
8806526036804 |
8806526036811 |
|
|
| ÁÖ¼ººÐÄÚµå |
116902ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¼ö¼úÈÄ․ºÐ¸¸ÈÄ ±â´É¼º ¿äÁ¤Ã¼, ¹æ±¤ÀÇ ½Å°æ¼º ±ÙÀÌ¿ÏÁõ
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ : 1ȸ 10 ~ 25¹Ð¸®±×·¥À» 1ÀÏ 3 ~ 4ȸ Åõ¿©ÇÑ´Ù.
½Ä»ç Á÷ÈÄ ÀÌ ¾àÀ» º¹¿ëÇÒ °æ¿ì ¸Þ½º²¨¿ò, ±¸Åä µîÀÇ Áõ»óÀÌ ¹ß»ýÇÒ ¼ö ÀÖÀ¸¹Ç·Î °øº¹¿¡ º¹¿ëÇÏ´Â °ÍÀ» ±ÇÀåÇÑ´Ù.
|
| ±Ý±â |
1) À§Àå°ü ¶Ç´Â ¿ä·ÎÀÇ ±â°èÀû Æó¼â°¡ Àִ ȯÀÚ
2) °æ·Ã¼º À§ÀåÁúȯ, À§±Ë¾ç, ±Þ¼ºÀ§Àå°ü ¿°Áõ¼º Áúȯ
3) º¹¸·¿° ȯÀÚ
4) ¹ÌÁֽŰæ±äÀåÇ×ÁøÈ¯ÀÚ
5) õ½ÄȯÀÚ
6) °©»ó¼±±â´ÉÇ×ÁøÁõȯÀÚ
7) °ü»óµ¿¸ÆÆó¼âȯÀÚ
8) ¼¸Æ, ¹æ½ÇÀüµµÀå¾Ö, Ç÷°ü¿îµ¿ºÒ¾ÈÁ¤¼ºÈ¯ÀÚ
9) ÀúÇ÷¾Ð, °íÇ÷¾ÐȯÀÚ
10) ½É±Ù°æ»öÁõȯÀÚ, ÁßÁõ½ÉÁúȯȯÀÚ
11) °£Áú ¹× ÆÄŲ½¼ÁõȯÀÚ
12) Ç×Äݸ°¿¡½ºÅ×¶óÁ¦·Î Ä¡·á¹Þ´Â ȯÀÚ
13) À§Àå°ü¹®ÇÕ¼úÀ» ¹ÞÀº ÈÄ Ä¡À¯µÇÁö ¾ÊÀº ȯÀÚ
14) ÀÓºÎ
|
| ½ÅÁßÅõ¿© |
ÀÌ ¾àÀº Ȳ»ö4È£(Ÿ¸£Æ®¶óÁø)¸¦ ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. |
| ÀÌ»ó¹ÝÀÀ |
1) ¼Òȱâ°è : ¶§¶§·Î ¼Ó¾²¸², º¹ºÎºÒÄè°¨, ±¸¿ª, ±¸Åä, À§°æ·Ã, ¼³»ç°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) ½Å °æ °è : ¶§¶§·Î ¹ßÇÑ, È«Á¶, Ÿ¾×ºÐºñ°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ¼øÈ¯±â°è : ƯÈ÷ ½É°èÇ×Áø, ÀúÇ÷¾ÐÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. °íÇ÷¾Ð ȯÀÚ¿¡¼ ªÀº ±â°£ÀÇ ½É¹æ¼º¼¼µ¿ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) °ú·®Åõ¿© : ½ÉÀåÁ¤Áö·Î ÀÎÇÑ ½Ç½Å, ÀϽÃÀûÀÎ ¿ÏÀü½Éºí·Ï, È£Èí°ï¶õ, ±â¸³¼º ÀúÇ÷¾Ð, ¹«ÀǽĹ躯, ¿äÀÇ Àý¹Ú µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) ±âŸ : ¶§¶§·Î õ½Ä¼º ¹ßÀÛ(ƯÈ÷ õ½ÄȯÀÚ¿¡¼), ÈäºÎ±ä¹Ú°¨, µÎÅë, ºÒÄè°¨ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) Äû´Ïµò ¹× ÇÁ·ÎÄ«Àξƹ̵å´Â Äݸ°È¿°ú¿¡ ±æÇ×ÀÛ¿ëÀ» ³ªÅ¸³»¹Ç·Î ÀÌ ¾àÀ» º´¿ë Åõ¿©ÇÒ °æ¿ì ÁÖÀǸ¦ ¿äÇÑ´Ù.
2) Äݸ°¼º¾à¹° ƯÈ÷ Äݸ°¿¡½ºÅ×¶óÁ¦ ¾ïÁ¦Á¦¿Í º´¿ëÇÒ °æ¿ì »ó½ÂÈ¿°ú°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù.
3) ±³°¨½Å°æÂ÷´ÜÁ¦¸¦ º¹¿ëÇϴ ȯÀÚ¿¡°Ô Åõ¿©ÇÏ¸é ½ÉÇÑ º¹ºÎÁõ»ó¿¡ ÀÕ´Þ¾Æ ±Þ°ÝÇÑ Ç÷¾Ð°Çϰ¡ ÀϾ ¼ö ÀÖÀ¸¹Ç·Î Ưº°È÷ À¯ÀÇÇÑ´Ù.
|
| Off-label Usage |
[Á¶È¸]
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
ÀÓ»êºÎ ¶Ç´Â ÀӽŰèȹÁß º¹¿ë±ÝÁö |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Bethanechol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Bethanechol acts by selectively stimulating muscarinic receptors in the parasympathetic nervous system, inducing no affect on nicotinic receptors.
|
| Pharmacology |
Bethanechol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Bethanechol is a parasympathomimetic (cholinergic) used for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention. Bethanechol, a cholinergic agent, is a synthetic ester which is structurally and pharmacologically related to acetylcholine. It increases the tone of the detrusor urinae muscle, usually producing a contraction sufficiently strong to initiate micturition and empty the bladder. It stimulates gastric motility, increases gastric tone, and often restores impaired rhythmic peristalsis. Bethanechol chloride is not destroyed by cholinesterase and its effects are more prolonged than those of acetytcholine.
|
| Metabolism |
Bethanechol¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Bethanechol¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Bethanechol¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Bethanechol¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
Bethanechol ChlorideÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ :
- °æ±¸ : 30-90ºÐ À̳»
- ÇÇÇÏÁÖ»ç : 5-15ºÐ À̳»
- ÀÛ¿ëÁö¼Ó½Ã°£ :
- °æ±¸ : Àú¿ë·®¿¡¼ 1½Ã°£, °í¿ë·®¿¡¼ 6½Ã°£ ±îÁö
- ÇÇÇÏÁÖ»ç : 2½Ã°£
- Èí¼ö : °æ±¸ : °³Ã¼Â÷°¡ Å
|
| Biotransformation |
Bethanechol¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Bethanechol¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Bethanechol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Bethanechol¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take on empty stomach: 1 hour before or 2 hours after meals to avoid nausea.
|
| Drug Target |
[Drug Target]
|
| Description |
Bethanechol¿¡ ´ëÇÑ Description Á¤º¸ A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, cardiac rate changes, and bronchial spasms. [PubChem]
|
| Drug Category |
Bethanechol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Muscarinic AgonistsParasympathomimetics
|
| Smiles String Canonical |
Bethanechol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C[N+](C)(C)C)OC(N)=O
|
| Smiles String Isomeric |
Bethanechol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@H](C[N+](C)(C)C)OC(N)=O
|
| InChI Identifier |
Bethanechol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C7H16N2O2/c1-6(11-7(8)10)5-9(2,3)4/h6H,5H2,1-4H3,(H-,8,10)/p+1/fC7H17N2O2/h8H2/q+1
|
| Chemical IUPAC Name |
Bethanechol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-carbamoyloxypropyl-trimethylazanium
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-11-03
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|